MARKET

EYPT

EYPT

EyePoint
NASDAQ
16.94
+0.28
+1.68%
Opening 15:56 12/18 EST
OPEN
16.87
PREV CLOSE
16.66
HIGH
17.43
LOW
16.52
VOLUME
1.09M
TURNOVER
--
52 WEEK HIGH
19.11
52 WEEK LOW
3.910
MARKET CAP
1.40B
P/E (TTM)
-5.6663
1D
5D
1M
3M
1Y
5Y
1D
EyePoint Inc. to Present at J.P. Morgan Healthcare Conference
Reuters · 1d ago
EyePoint Grants Stock Options to New Employees as Inducement Awards
Reuters · 2d ago
EYEPOINT REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 2d ago
Buy Recommendation for EyePoint Pharmaceuticals: Strong Clinical Positioning and Market Potential of Duravyu in Wet AMD
TipRanks · 3d ago
Weekly Report: what happened at EYPT last week (1208-1212)?
Weekly Report · 3d ago
Buy Recommendation for EyePoint Pharmaceuticals: Strategic Positioning and Promising Wet AMD Therapy
TipRanks · 12/11 16:45
Mizuho remains bullish on EyePoint as competitor makes move for ‘Pole Position’
TipRanks · 12/09 16:15
EyePoint Pharmaceuticals: Strategic Positioning and Competitive Edge Reinforce Buy Rating
TipRanks · 12/09 16:05
More
About EYPT
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.

Webull offers EyePoint Inc stock information, including NASDAQ: EYPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EYPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EYPT stock methods without spending real money on the virtual paper trading platform.